原研机构 |
非在研机构 |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评特殊审批 (中国) |
分子式C26H32N4O5 |
InChIKeyGPHPBXRKAJSSIC-UHFFFAOYSA-N |
CAS号1228559-81-6 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
反流性食管炎 | 申请上市 | 中国 | 2023-02-10 | |
反流性食管炎 | 申请上市 | 中国 | 2023-02-10 | |
胃食管反流 | 临床3期 | 中国 | 2022-01-30 | |
十二指肠溃疡 | 临床2期 | 中国 | - | |
幽门螺杆菌感染 | 临床2期 | 中国 | - | |
胃溃疡 | 临床1期 | 中国 | 2018-10-23 | |
食管炎 | 临床1期 | 瑞典 | - |
临床2期 | 248 | (X842 25 mg BID) | 網選憲壓網艱鬱醖積製(鹹鹽夢衊鹹獵糧廠鏇蓋) = 艱觸構鹹夢製構範廠廠 鏇獵構積蓋顧顧窪積選 (憲淵網糧蓋鹽顧鹽襯憲, 憲簾鏇壓壓繭艱憲願簾 ~ 糧艱憲簾鹹糧齋醖遞夢) 更多 | - | 2023-11-01 | ||
(X842 50 mg BID) | 網選憲壓網艱鬱醖積製(鹹鹽夢衊鹹獵糧廠鏇蓋) = 蓋衊膚鬱繭網遞艱鏇憲 鏇獵構積蓋顧顧窪積選 (憲淵網糧蓋鹽顧鹽襯憲, 願廠網鹽蓋餘製窪鬱製 ~ 鹽鬱繭簾鏇餘積廠獵鹹) 更多 | ||||||
N/A | - | 衊窪壓顧襯遞窪顧構鏇(網鏇淵構憲顧鬱淵簾襯) = In the double-blind period (Week 1-4), treatment-emergent adverse events (TEAEs) were reported by 18.2% of patients treated with LG (all 4 doses), and by 18.0% of patients treated with LAN. 2 patients (0.8%) experienced serious TEAEs (25 mg dosing group: severe cholecystitis; 75 mg dosing group: moderate laryngospasm), with both events being considered by the Investigator as unlikely related to study treatment. 8 patients (3.2%) presented with at least one TEAE considered by the Investigator as related to study drug. Treatment was discontinued in 5 patients (2.0%) due to TEAEs (25 mg dosing group: severe cholecystitis, mild diarrhea; 100 mg dosing group: moderate esophageal pain, moderate regurgitation; lansoprazole group: mild nausea, mild chest pain, mild fatigue, mild COVID-19). For the entire study period (Week 1-8), TEAEs were reported by 23.0% of patients. The most commonly reported TEAEs are presented in Table 1. No deaths, nor any adverse events of special interest, were reported in the study. No notable differences between the treatment groups were observed with regards to clinical laboratory evaluation, vital signs, physical findings, or other observations related to safety. 糧簾壓蓋醖夢襯憲築選 (繭網窪願製製獵積觸構 ) | - | 2023-10-15 | |||
Linaprazan glurate 50 mg |